A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Molavi B, Rassouli N, Bagwe S, Rasouli N. Central Arkansas Veterans Healthcare System, Little Rock, Arkansas 72205, USA. Vasc Health Risk Manag. 2007;3(6):967-73. PMID: 18200815 The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin. Thiazolidinediones review pubmed search wiki thiazolidinediones Recent Related References: 3D-QSAR Studies on a Series of 5-Arylidine-2, 4-Thiazolidinediones as Aldose Reductase Inhibitors: A Self-Organizing Molecular Field Analysis Approach. Thareja S, Aggarwal S, Bhardwaj TR et al. Med Chem. 2010 Mar 11. PMID: 20218967 Diabetes Medications Related to an Increased Risk of Falls and Fall-Related Morbidity in the Elderly (April). Berlie HD, Garwood CL. Ann Pharmacother. 2010 Mar 9. PMID: 20215495 Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells. Yoshizaki T, Motomura W, Tanno S et al. J Exp Clin Cancer Res. 2010 Mar 10. PMID: 20214829 Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes. Samtani MN. Biopharm Drug Dispos. 2010 Mar 8. PMID: 20213855 A New Concept Underlying Stem Cell Lineage Skewing That Explains the Detrimental Effects of Thiazolidinediones on Bone. Bruedigam C, Eijken M, Koedam M et al. Stem Cells. 2010 Mar 8. PMID: 20213769 Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes: The ACCORD Eye Substudy. Ambrosius WT, Danis RP, Goff DC Jr et al. Arch Ophthalmol. 2010 Mar. PMID: 20212201 Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease. Reilly JB, Berns JS. Semin Dial. 2010 Feb 22. PMID: 20210915 Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone versus Rosiglitazone. Simó R, Rodriguez A, Caveda E. Curr Drug Saf. 2010 Mar 7. PMID: 20210732 Cytokines (interferon-gamma and tumor necrosis factor-alpha)-induced nuclear factor-kappaB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Antonelli A, Ferrari SM, Fallahi P et al. Metabolism. 2010 Mar 5. PMID: 20206950 Rosiglitazone Reduces Plasma Levels of Inflammatory and Hemostatic Biomarkers and Improves Global Endothelial Function in Habitual Heavy Smokers Without Diabetes Mellitus or Metabolic Syndrome. Chen IC, Chao TH, Tsai WC et al. J Formos Med Assoc. 2010 Feb. PMID: 20206835 Self-organizing molecular field analysis of 2,4-thiazolidinediones: A 3D-QSAR model for the development of human PTP1B inhibitors. Thareja S, Aggarwal S, Bhardwaj TR et al. Eur J Med Chem. 2010 Feb 20. PMID: 20236737 Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Barnett AH, Cradock S, Fisher M et al. Int J Clin Pract. 2010 Mar 5. PMID: 20236369 PS2-20: Racial Disparities in A1c Change and Medication Intensification. Rush WA, Crain AL, Amundson GH et al. Clin Med Res. 2010 Mar. PMID: 20305209 [Biomedical research, the market, clinicians, safety and corporate social responsibility post-phase III: Maintaining confidence.] Marín-Gámez N, Kessel-Sardiñas H, Cervantes-Bonet B et al. Rev Calid Asist. 2010 Mar 19. PMID: 20304693 Glucose Supply and Insulin Demand Dynamics of Antidiabetic Agents. Monte SV, Schentag JJ, Adelman MH et al. J Diabetes Sci Technol. 2010 Mar 1. PMID: 20307399 Predictors of Annual Pharmaceutical Costs in Australia for Community-Based Individuals with, or at Risk of, Cardiovascular Disease: Analysis of Australian Data from the REACH Registry. Ademi Z, Liew D, Hollingsworth B et al. Am J Cardiovasc Drugs. 2010 Apr 1. PMID: 20334445 Ensuring integrity in industry-sponsored research: primum non nocere, revisited. DeAngelis CD, Fontanarosa PB. JAMA. 2010 Mar 24. PMID: 20332409 Setting the RECORD Straight. Nissen SE. JAMA. 2010 Mar 24. PMID: 20332408 Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. Wang AT, McCoy CP, Murad MH et al. BMJ. 2010 Mar 18. PMID: 20299696 Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Defronzo RA. Diabetologia. 2010 Apr 2. PMID: 20361178 Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Albers HM, Dong A, van Meeteren LA et al. Proc Natl Acad Sci U S A. 2010 Apr 1. PMID: 20360563 Review article: Thiazolidinediones and heart failure. Chaggar PS, Shaw SM, Williams SG. Diab Vasc Dis Res. 2009 Jul. PMID: 20368206 Review article: Thiazolidinediones and heart failure. Chaggar PS, Shaw SM, Williams SG. Diab Vasc Dis Res. 2009 Jul. PMID: 20368206 Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin. Petrovic V, Costa RH, Lau LF et al. Cancer Biol Ther. 2010 Jun 6. PMID: 20372080 Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Barnett AH. Curr Med Res Opin. 2010 Apr 6. PMID: 20370379 In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. Kos K, Wong SP, Huda MS et al. Diabetes Obes Metab. 2010 Apr. PMID: 20380658 In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. Kos K, Wong SP, Huda MS et al. Diabetes Obes Metab. 2010 Apr. PMID: 20380658 Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. Phung OJ, Scholle JM, Talwar M et al. JAMA. 2010 Apr 14. PMID: 20388897 Saxagliptin in type 2 diabetes. Billiones R. Drugs Today (Barc). 2010 Feb. PMID: 20393638 Fibrates, glitazones, and peroxisome proliferator-activated receptors. Lalloyer F, Staels B. Arterioscler Thromb Vasc Biol. 2010 May. PMID: 20393155 Minireview: Nuclear Hormone Receptor 4A Signaling: Implications for Metabolic Disease. Pearen MA, Muscat GE. Mol Endocrinol. 2010 Apr 14. PMID: 20392876 Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice. Duan SZ, Usher MG, Foley EL 4th et al. Diabetologia. 2010 Apr 17. PMID: 20401461 A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy. Raboud JM, Diong C, Carr A et al. HIV Clin Trials. 2010 Jan-Feb. PMID: 20400410 3D-QSAR Studies on a Series of 5-Arylidine-2, 4-Thiazolidinediones as Aldose Reductase Inhibitors: A Self-Organizing Molecular Field Analysis Approach. Thareja S, Aggarwal S, Bhardwaj TR et al. Med Chem. 2010 Jan. PMID: 20402658 Rosiglitazone in the UK: down but not out. Iheanacho I. BMJ. 2010 Apr 7. PMID: 20375092 Rosiglitazone, marketing, and medical science. Moynihan R. BMJ. 2010 Apr 7. PMID: 20375091 Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. Yamanouchi T. Vasc Health Risk Manag. 2010 Apr 15. PMID: 20407626 Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. Glatz T, Stöck I, Nguyen-Ngoc M et al. J Hypertens. 2010 Apr 20. PMID: 20410836 Therapy of nonalcoholic fatty liver disease: current status. Duvnjak M, Tomasic V, Gomercic M et al. J Physiol Pharmacol. 2009 Dec. PMID: 20388946 Therapy of nonalcoholic fatty liver disease: current status. Duvnjak M, Tomasic V, Gomercic M et al. J Physiol Pharmacol. 2009 Dec. PMID: 20388946 Diabetes, insulin, insulin analogues, and cancer. Müssig K, Staiger H, Kantartzis K et al. Dtsch Med Wochenschr. 2010 May. PMID: 20425680 Update on the safety of thiazolidinediones. Lieb DC, McCall AL. Curr Diab Rep. 2010 Apr. PMID: 20425570 Troglitazone, a Ligand of Peroxisome Proliferator-Activated Receptor-{gamma}, Stabilizes NUCB2 (Nesfatin) mRNA by Activating the ERK1/2 Pathway: Isolation and Characterization of the Human NUCB2 Gene. Yamada M, Horiguchi K, Umezawa R et al. Endocrinology. 2010 Apr 28. PMID: 20427483 Glucose control in hospitalized patients. Sawin G, Shaughnessy AF. Am Fam Physician. 2010 May 1. PMID: 20433128 NASH: Thiazolidinediones for NASH--one pill doesn't fix everything. Neuschwander-Tetri BA. Nat Rev Gastroenterol Hepatol. 2010 May. PMID: 20442730 Composite end points in clinical trials. Sheehe PR. JAMA. 2010 May 5. PMID: 20442384 Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. Kaul S, Bolger AF, Herrington D et al. J Am Coll Cardiol. 2010 Apr 27. PMID: 20413044 Effects of long-term pioglitazone treatment on peripheral and central markers of aging. Blalock EM, Phelps JT, Pancani T et al. PLoS One. 2010 Apr 29. PMID: 20454453 Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Eto K, Tumenbayar B, Nagashima SI et al. Diabetes Res Clin Pract. 2010 May 6. PMID: 20452080 What is the best management strategy for patients with severe insulin resistance? Semple RK, Williams R, Dunger DB. Clin Endocrinol (Oxf). 2010 Apr 23. PMID: 20455892 Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 Diabetes (June) (CE). Borja-Hart NL, Whalen KL. Ann Pharmacother. 2010 May 11. PMID: 20460554 Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: Data from a randomized, placebo-controlled, double-blind study. Walcher T, Walcher D, Hetzel J et al. Diab Vasc Dis Res. 2010 May 11. PMID: 20460360 Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database. Zhang Q, Mavros P, Engel SS et al. Curr Med Res Opin. 2010 May 13. PMID: 20465367 Managing type 2 diabetes: balancing HbA1c and body weight. Mavian AA, Miller S, Henry RR. Postgrad Med. 2010 May. PMID: 20463420 New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals. Wysham CH. Postgrad Med. 2010 May. PMID: 20463414 Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Derosa G, Maffioli P. Diabetes Technol Ther. 2010 Jun. PMID: 20470234 Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Tilg H, Moschen A. Minerva Gastroenterol Dietol. 2010 Jun. PMID: 20485253 The Effect of Oral Antidiabetic Agents on Glycated Hemoglobin Levels: A Systematic Review and Meta-Analysis. Sherifali D, Nerenberg K, Pullenayegum E et al. Diabetes Care. 2010 May 18. PMID: 20484130 Hydrochloride pioglitazone decreases urinary TGF-beta1 excretion in type 2 diabetics. Hu YY, Ye SD, Zhao LL et al. Eur J Clin Invest. 2010 May 17. PMID: 20482594 Treatment of dyslipidemia in HIV-infected patients. Sekhar RV, Balasubramanyam A. Expert Opin Pharmacother. 2010 May 20. PMID: 20486828 Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of PPAR{gamma} activation in mice. Huo Y, Guo X, Xu K et al. J Biol Chem. 2010 May 24. PMID: 20498376 Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option? Säemann MD, Krebs M. Wien Klin Wochenschr. 2010 Apr. PMID: 20503018 Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4. Arbones-Mainar JM, Johnson LA, Altenburg MK et al. FASEB J. 2010 May 25. PMID: 20501792 High-Sensitivity C-Reactive Protein Predicts Cardiovascular Risk in Diabetic and Nondiabetic Patients: Effects of Insulin-Sensitizing Treatment with Pioglitazone. Pfützner A, Schöndorf T, Hanefeld M et al. J Diabetes Sci Technol. 2010 May 1. PMID: 20513338 Rosiglitazone Attenuates Endothelin-1-Induced Vasoconstriction by Upregulating Endothelial Expression of Endothelin B Receptor. Tian J, Wong WT, Tian XY et al. Hypertension. 2010 Jun 1. PMID: 20516393 Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? Campbell IW. Int J Clin Pract. 2010 May. PMID: 20518953 Pathophysiology of diabetes in elderly people. Paolisso G. Acta Biomed. 2010. PMID: 20518191 GSK is accused of trying to suppress editorial on rosiglitazone. Tanne JH. BMJ. 2010 May 19. PMID: 20484354 An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells. Sturek JM, Castle JD, Trace AP et al. J Clin Invest. 2010 Jun 7. PMID: 20530872 Thiazolinedione treatment in PCOS - an update. Glintborg D, Andersen M. Gynecol Endocrinol. 2010 Jun 9. PMID: 20528570 Discovery and Optimization of Boronic Acid Based Inhibitors of Autotaxin. Albers HM, van Meeteren LA, Egan DA et al. J Med Chem. 2010 Jun 10. PMID: 20536182 Thiazolidinediones as a Novel Class of Algicides Against Red Tide Harmful Algal Species. Kim YM, Wu Y, Duong TU et al. Appl Biochem Biotechnol. 2010 Jun 11. PMID: 20544303 Novel treatment modalities for Graves' orbitopathy. Bartalena L, Lai A, Sassi L et al. Pediatr Endocrinol Rev. 2010 Mar. PMID: 20467365 Diabetes mellitus, hyperglycaemia and cancer. Simon D, Balkau B. Diabetes Metab. 2010 May 27. PMID: 20554237 Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Yu J, Shen B, Chu ES et al. Hepatology. 2010 Jun. PMID: 20512989 Colon OCTN2 gene expression is up-regulated by PPAR{gamma} in humans and mice, and contributes to local and systemic carnitine homeostasis. D'Argenio G, Petillo O, Margarucci S et al. J Biol Chem. 2010 Jun 17. PMID: 20558736 Comparison of Pioglitazone vs Glyburide in Early Heart Failure: Insights From a Randomized Controlled Study of Patients With Type 2 Diabetes and Mild Cardiac Disease. Giles TD, Elkayam U, Bhattacharya M et al. Congest Heart Fail. 2010 May 1. PMID: 20557330 Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues. Mitka M. JAMA. 2010 Jun 16. PMID: 20551399 Avandia outcome may signal change in epidemiologists' sway. Wadman M. Nat Med. 2010 Jun. PMID: 20526293 GlaxoSmithKline denies it has settled thousands of lawsuits over rosiglitazone (Avandia). Tanne JH. BMJ. 2010 Jun 7. PMID: 20530068 A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Musso G, Gambino R, Cassader M et al. Hepatology. 2010 Mar 1. PMID: 20578268 Pharmacologic Prophylaxis of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Beyond beta-Blockers. Davis EM, Packard KA, Hilleman DE. Pharmacotherapy. 2010 Jul. PMID: 20575638 Bone loss and fracture risk associated with thiazolidinedione therapy. Riche DM, Travis King S. Pharmacotherapy. 2010 Jul. PMID: 20575635 Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD). Bilik D, McEwen LN, Brown MB et al. Pharmacoepidemiol Drug Saf. 2010 May 17. PMID: 20583206 Pioglitazone in chemically induced mammary carcinogenesis in rats. Bojková B, Garajová M, Kajo K et al. Eur J Cancer Prev. 2010 Jun 24. PMID: 20581687 Rosiglitazone, thiazolidinediones and atherosclerosis. Dandona P, Chaudhuri A, Ghanim H. Atherosclerosis. 2010 Jun 8. PMID: 20580364 Diabetes: making sense of the rosiglitazone controversy. Farkouh ME, Fuster V. Nat Rev Cardiol. 2010 Jul. PMID: 20577297 Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. Botton T, Puissant A, Cheli Y et al. Cell Death Differ. 2010 Jul 2. PMID: 20596077 A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. McEwan P, Evans M, Bergenheim K. Diabetes Obes Metab. 2010 Jul. PMID: 20590737 Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: Implications for the evaluation of antidiabetic drugs. Gerstein HC, Yusuf S. Am Heart J. 2010 Jul. PMID: 20598964 Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Hsiao FY, Tsai YW, Wen YW et al. Pharmacoepidemiol Drug Saf. 2010 Jul 2. PMID: 20607752 Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors. Pavlov TS, Imig JD, Staruschenko A. PPAR Res. 2010. PMID: 20613963 Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects. Bocciardi R, Ravazzolo R. PPAR Res. 2010. PMID: 20613955 Lipid-induced insulin resistance: unravelling the mechanism. Samuel VT, Petersen KF, Shulman GI. Lancet. 2010 Jun 26. PMID: 20609972 [Diabetes mellitus, thiazolidinediones and fractures: an unfinished story.] Silva AG, Lazaretti-Castro M. Arq Bras Endocrinol Metabol. 2010 Jun. PMID: 20625645 Study confirms link between certain diabetes drugs and fractures. . Harv Womens Health Watch. 2010 May. PMID: 20593558 Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes. Bilik D, McEwen LN, Brown MB et al. J Clin Endocrinol Metab. 2010 Jul 14. PMID: 20631021 Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, Xie C, Do R et al. Diabetes Care. 2010 Jul 13. PMID: 20628086 Interventional studies for polycystic ovarian syndrome in children and adolescents. Vuguin PM. Ped Health. 2010 Feb. PMID: 20640230 Diabetic Macular Edema: Correlations with Available Diabetes Therapies - Evidence Across a Qualitative Review of Published Literature from MEDLINE and EMBASE. Merante D, Menchini F, Truitt KE et al. Drug Saf. 2010 Aug 1. PMID: 20635822 Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Waugh N, Cummins E, Royle P et al. Health Technol Assess. 2010 Jul. PMID: 20646668 Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study. Banerji MA, Purkayastha D, Francis BH. Diabetes Res Clin Pract. 2010 Jul 22. PMID: 20655609 Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Mabilleau G, Mieczkowska A, Edmonds ME. Diabet Med. 2010 Aug. PMID: 20653751 FDA committee urges tight restrictions on rosiglitazone. Roehr B. BMJ. 2010 Jul 16. PMID: 20639290 Intracellular Ca2+ can compensate for the lack of NADPH oxidase-derived ROS in endothelial cells. Lee M, Spokes KC, Aird WC et al. FEBS Lett. 2010 Jul 16. PMID: 20621840 Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4-thiazolidinedione derivatives. Patil V, Tilekar K, Mehendale-Munj S et al. Eur J Med Chem. 2010 Jul 11. PMID: 20667627 Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4-thiazolidinedione derivatives. Patil V, Tilekar K, Mehendale-Munj S et al. Eur J Med Chem. 2010 Jul 11. PMID: 20667627 PPARgamma and chronic kidney disease. Fogo AB. Pediatr Nephrol. 2010 Jul 30. PMID: 20676693 Thiazolidinediones and cardiovascular risk - a question of balance. Erdmann E, Charbonnel B, Wilcox R. Curr Cardiol Rev. 2009 Aug. PMID: 20676274 Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin. Galli A, Ceni E, Mello T et al. Hepatology. 2010 Aug. PMID: 20683949 Synthesis and antidiabetic activity of some new chromonyl-2,4-thiazolidinediones. Ceylan-Ünlüsoy M, Verspohl EJ, Ertan R. J Enzyme Inhib Med Chem. 2010 Aug 5. PMID: 20687791 Long-Term Effects of Pioglitazone on Carotid Atherosclerosis in Japanese Patients with Type 2 Diabetes without a Recent History of Macrovascular Morbidity. Yamasaki Y, Katakami N, Furukado S et al. J Atheroscler Thromb. 2010 Jul 31. PMID: 20686324 Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion. Gamboa J, Blankenship D, Niemi JP et al. Neuroscience. 2010 Aug 4. PMID: 20691766 Dipeptidylpeptitase-4 inhibitors (gliptins): focus on drug-drug interactions. Scheen AJ. Clin Pharmacokinet. 2010 Sep 1. PMID: 20690781 FDA puts rosiglitazone post-marketing trial on hold. Cohen D. BMJ. 2010 Jul 26. PMID: 20660507 Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease. Siew ED, Ikizler TA. Semin Dial. 2010 Jul. PMID: 20701717 Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. Shi L, Zhao Y, Szymanski K et al. J Diabetes Complications. 2010 Aug 11. PMID: 20708416 Avandia panel member may be investigated for possible conflicts of interest. Tanne JH. BMJ. 2010 Aug 3. PMID: 20682621 Incretin-Based Therapies: Review of the Outpatient Literature with Implications for Use in the Hospital and After Discharge. Bode B Md, Amin A Md. Hosp Pract (Minneap). 2009 Dec. PMID: 20720383 The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. Nicolakakis N, Hamel E. Front Aging Neurosci. 2010 May 21. PMID: 20725514 Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Katsiki N, Hatzitolios AI. Curr Opin Obstet Gynecol. 2010 Aug 18. PMID: 20724929 Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience. Foley JE, Jordan J. Vasc Health Risk Manag. 2010 Aug 9. PMID: 20730070 Risk of Cardiovascular Events and All-Cause Mortality in Patients Treated With Thiazolidinediones in a Managed-Care Population. Wertz DA, Chang CL, Sarawate CA et al. Circ Cardiovasc Qual Outcomes. 2010 Aug 24. PMID: 20736441 Risk of Cardiovascular Events and All-Cause Mortality in Patients Treated With Thiazolidinediones in a Managed-Care Population. Wertz DA, Chang CL, Sarawate CA et al. Circ Cardiovasc Qual Outcomes. 2010 Aug 24. PMID: 20736441 Stimulation of ENaC Activity by Rosiglitazone is PPARgamma-Dependent and Correlates with SGK1 Expression Increase. Renauld S, Tremblay K, Ait-Benichou S et al. J Membr Biol. 2010 Aug 26. PMID: 20740360 Epinephrine Mediated Regulation of PDK4 mRNA in Rat Adipose Tissue. Wan Z, Thrush AB, Legare M et al. Am J Physiol Cell Physiol. 2010 Aug 25. PMID: 20739620 Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. Dunn FL, Higgins LS, Fredrickson J et al. J Diabetes Complications. 2010 Aug 23. PMID: 20739195 Modulation of Pantothenate Kinase 3 Activity by Small Molecules that Interact with the Substrate/Allosteric Regulatory Domain. Leonardi R, Zhang YM, Yun MK et al. Chem Biol. 2010 Aug 27. PMID: 20797618 Modulation of Pantothenate Kinase 3 Activity by Small Molecules that Interact with the Substrate/Allosteric Regulatory Domain. Leonardi R, Zhang YM, Yun MK et al. Chem Biol. 2010 Aug 27. PMID: 20797618 Cytotoxic effects of statins and thiazolidinediones on meningioma cells. Gehring S, Tapia-Pérez JH, Kirches E et al. J Neurooncol. 2010 Aug 30. PMID: 20803306 Is there a role for the nuclear receptor PPARgamma in neuropsychiatric diseases? García-Bueno B, Pérez-Nievas BG, Leza JC. Int J Neuropsychopharmacol. 2010 Aug 27. PMID: 20800014 Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Kurukulasuriya LR, Sowers JR. Cardiovasc Diabetol. 2010 Aug 30. PMID: 20804556 Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells. Freudlsperger C, Dahl A, Hoffmann J et al. Phytother Res. 2010 Sep. PMID: 20812278 In Vitro Evaluation of Inhibitory Effects of Antidiabetic and Antihyperlipidemic Drugs on Human Carboxylesterase Activities. Fukami T, Takahashi S, Nakagawa N et al. Drug Metab Dispos. 2010 Sep 1. PMID: 20810539 Mechanisms of adiponectin regulation and use as a pharmacological target. Phillips SA, Kung JT. Curr Opin Pharmacol. 2010 Aug 30. PMID: 20810317 Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis. Lecka-Czernik B. Curr Osteoporos Rep. 2010 Sep 1. PMID: 20809203 PPARgamma: a circadian transcription factor in adipogenesis and osteogenesis. Kawai M, Rosen CJ. Nat Rev Endocrinol. 2010 Sep 7. PMID: 20820194 Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones? Freemantle N. BMJ. 2010 Sep 6. PMID: 20819888 Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. Okumura T. J Gastroenterol. 2010 Sep 8. PMID: 20824291 Effects of metformin on rosiglitazone-induced cardiac hypertrophy in mice. Lee HH, Yeh CH, Chen YT et al. Biol Pharm Bull. 2010. PMID: 20823565 Improving treatment success rates for type 2 diabetes: recommendations for a changing environment. Triplitt C. Am J Manag Care. 2010 Aug. PMID: 20809668 Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Garber AJ. Am J Manag Care. 2010 Aug. PMID: 20809667 Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. Derosa G, Maffioli P. Diabetes Res Clin Pract. 2010 Sep 8. PMID: 20832133 Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. Sultana G, Kapur P, Aqil M et al. J Clin Pharm Ther. 2010 Jun 1. PMID: 20831529 (Z)-5-(4-methoxybenzylidene) thiazolidine-2, 4-dione ameliorates the adjuvant-induced arthritis via inhibiting the migration of macrophage and down-regulating the cytokine mRNA expression. Ma Y, Wang X, Wu X et al. Int Immunopharmacol. 2010 Sep 10. PMID: 20837171 Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Yessoufou A, Wahli W. Swiss Med Wkly. 2010 Sep 15. PMID: 20842602 Thiazolidinediones: A 2010 Perspective. Krishnaswami A, Ravi-Kumar S, Lewis JM. Perm J. 2010 Fall. PMID: 20844707 Thiazolidinediones upregulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor {gamma}-independent pathway. Higashi Y, Holder K, Delafontaine P. J Biol Chem. 2010 Sep 15. PMID: 20843793 Thiazolidinedione use and ulcerative colitis-related flares: An exploratory analysis of administrative data. Lund JL, Stürmer T, Porter CQ et al. Inflamm Bowel Dis. 2010 May 19. PMID: 20848530 Differential effects of PPARgamma ligands on oxidative stress-induced death of retinal pigmented epithelial cells. Rodrigues GA, Maurier-Mahé F, Shurland DL et al. Invest Ophthalmol Vis Sci. 2010 Sep 16. PMID: 20847119 Subchronic treatment of rats with oxytocin results in improved adipocyte differentiation and increased gene expression of factors involved in adipogenesis. Eckertova M, Ondrejcakova M, Krskova K et al. Br J Pharmacol. 2010 Sep 15. PMID: 20846187 Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Pinkney J, Fox T, Ranganath L. Ther Clin Risk Manag. 2010 Sep 7. PMID: 20856686 PPAR{gamma}-Dependent Regulation of Adenylate Cyclase 6 Amplifies the Stimulatory Effect of cAMP on Renin Gene Expression. Desch M, Schubert T, Schreiber A et al. Mol Endocrinol. 2010 Sep 22. PMID: 20861226 Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a Tissue Doppler Imaging study. Naka KK, Pappas K, Papathanassiou K et al. Cardiovasc Diabetol. 2010 Sep 23. PMID: 20863381 Anti-inflammatory Effects of Thiazolidinediones in Human Airway Smooth Muscle Cells. Zhu M, Flynt L, Ghosh S et al. Am J Respir Cell Mol Biol. 2010 Sep 24. PMID: 20870897 Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. Nishikawa K, Nakashima T, Takeda S et al. J Clin Invest. 2010 Sep 27. PMID: 20877012 Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs. Freeman JS. J Am Osteopath Assoc. 2010 Sep. PMID: 20876838 Alogliptin: a Novel Molecule for Improving Glycemic Control in Type II Diabetes Mellitus. Ghatak SB, Patel DS, Shanker N et al. Curr Diabetes Rev. 2010 Sep 27. PMID: 20879969 Diabetes and skeletal health. Yaturu S. J Diabetes. 2009 Dec. PMID: 20923525 Pharmacogenetics of Anti-Diabetes Drugs. Distefano JK, Watanabe RM. Pharmaceuticals (Basel). 2010 Aug 1. PMID: 20936101 Pharmacogenetics of Anti-Diabetes Drugs. Distefano JK, Watanabe RM. Pharmaceuticals (Basel). 2010 Aug 1. PMID: 20936101 Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis. Nishio K, Kobayashi Y. Cardiovasc Revasc Med. 2010 Oct-Dec. PMID: 20934654 Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis. Nishio K, Kobayashi Y. Cardiovasc Revasc Med. 2010 Oct-Dec. PMID: 20934654 [Rosiglitazone] Johansen K. Ugeskr Laeger. 2010 Sep 20. PMID: 20931733 [Rosiglitazone] Johansen K. Ugeskr Laeger. 2010 Sep 20. PMID: 20931733 The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: A meta-analysis. Zhao Y, He X, Huang C et al. Diabetes Res Clin Pract. 2010 Oct 4. PMID: 20926154 The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: A meta-analysis. Zhao Y, He X, Huang C et al. Diabetes Res Clin Pract. 2010 Oct 4. PMID: 20926154 Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. Hirose H, Yamamoto Y, Seino-Yoshihara Y et al. J Atheroscler Thromb. 2010 Oct 8. PMID: 20948162 Rosiglitazone and the need for a new drug safety agency. Garattini S, Bertele' V. BMJ. 2010 Oct 6. PMID: 20926483 Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Rakoski MO, Singal AG, Rogers MA et al. Aliment Pharmacol Ther. 2010 Nov. PMID: 20955440 Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis. Bruin JE, Petrik JJ, Hyslop JR et al. Endocrine. 2010 Apr. PMID: 20960268 Therapy: What evidence should guide the use of thiazolidinediones? Riddle MC. Nat Rev Endocrinol. 2010 Nov. PMID: 20962864 Effects of the peroxisome proliferator-activated receptor gamma agonist pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Park JS, Cho MH, Nam JS et al. Eur J Endocrinol. 2010 Oct 20. PMID: 20961967 Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. White AT, Murphy AN. J Neurochem. 2010 Nov. PMID: 20964688 PPARG independent thiazolidinedione-mediated inhibition of Nur77 expression in vascular Endothelial cells. Hu Y, Liu H, Simpson RW et al. J Endocrinol. 2010 Oct 26. PMID: 20978184 A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Liutkus J, Rosas Guzman J, Norwood P et al. Diabetes Obes Metab. 2010 Dec. PMID: 20977576 Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver. Rogue A, Spire C, Brun M et al. PPAR Res. 2010. PMID: 20981297 Review Article: Preservation of Beta Cell Function in Type 2 Diabetes. Nyalakonda K, Sharma T, Ismail-Beigi F. Endocr Pract. 2010 Jun 21. PMID: 21030360 Potential bone effects of thiazolidinediones in diabetic dialysis patients. Fourtounas C. Semin Dial. 2010 Sep. PMID: 21039879 Nutrition and psoriasis. Ricketts JR, Rothe MJ, Grant-Kels JM. Clin Dermatol. 2010 Nov-Dec. PMID: 21034986 Thiazolidinedione precipitated thyroid associated ophthalmopathy. Menaka R, Sehgal M, Lakshmi M et al. J Assoc Physicians India. 2010 Apr. PMID: 21046886 Metformin versus thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Li XJ, Yu YX, Liu CQ et al. Clin Endocrinol (Oxf). 2010 Nov 2. PMID: 21050251 Elevated vitamin D status in postmenopausal women on thiazolidinediones for type 2 diabetes. Chakreeyarat S, Saetung S, Chailurkit LO et al. Endocrine. 2010 Nov 11. PMID: 21069575 Antifibrotic Effects of Pioglitazone at Low Doses on the Diabetic Rat Kidney Are Associated with the Improvement of Markers of Cell Turnover, Tubular and Endothelial Integrity, and Angiogenesis. Toblli JE, Cao G, Giani JF et al. Kidney Blood Press Res. 2010 Nov 11. PMID: 21071958 Antifibrotic Effects of Pioglitazone at Low Doses on the Diabetic Rat Kidney Are Associated with the Improvement of Markers of Cell Turnover, Tubular and Endothelial Integrity, and Angiogenesis. Toblli JE, Cao G, Giani JF et al. Kidney Blood Press Res. 2010 Nov 11. PMID: 21071958 The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort. Roumie CL, Huizinga MM, Liu X et al. Pharmacoepidemiol Drug Saf. 2010 Nov 12. PMID: 21077108 Therapy: The second time as farce: rosiglitazone and the regulators. Gale EA. Nat Rev Endocrinol. 2010 Nov 23. PMID: 21102545 Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. Ramachandran S, Saraf S, Shetty C et al. Ann Clin Biochem. 2010 Nov 29. PMID: 21115572 Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells. Tapia-Pérez JH, Kirches E, Mawrin C et al. Cancer Chemother Pharmacol. 2010 Dec 1. PMID: 21120479 The potentially inappropriate prescription of new drug: thiazolidinediones for patients with type II diabetes in Taiwan. Wen YW, Tsai YW, Huang WF et al. Pharmacoepidemiol Drug Saf. 2010 Dec 1. PMID: 21125543 Diabetic nephropathy -- a multifaceted target of new therapies. Choudhury D, Tuncel M, Levi M. Discov Med. 2010 Nov. PMID: 21122472 The complexities of obesity, diabetes, and the development and progression of pancreatic cancer. Bao B, Wang Z, Li Y et al. Biochim Biophys Acta. 2010 Nov 30. PMID: 21129444 Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction after Lifestyle Changes? Athyros VG, Tziomalos K, Karagiannis A et al. Curr Pharm Des. 2010 Dec 3. PMID: 21128892 Proteomic characterization of thiazolidinedione regulation of obese adipose secretome in Zucker obese rats. Chen X, Hunt D, Cushman SW et al. Proteomics Clin Appl. 2009 Sep. PMID: 21137009 What to add in with metformin in type 2 diabetes? Petrie JR, Adler A, Vella S. QJM. 2010 Dec 13. PMID: 21156663 Differential Effects of PPAR-{gamma} Activation versus Chemical or Genetic Reduction of DPP-4 Activity on Bone Quality in Mice. Kyle KA, Willett TL, Baggio LL et al. Endocrinology. 2010 Dec 22. PMID: 21177828 Immunomodulatory effects of eicosapentaenoic acid through induction of regulatory T cells. Iwami D, Nonomura K, Shirasugi N et al. Int Immunopharmacol. 2010 Dec 17. PMID: 21182821 The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort. Roumie CL, Huizinga MM, Liu X et al. Pharmacoepidemiol Drug Saf. 2011 Jan. PMID: 21182152 The potentially inappropriate prescription of new drug: thiazolidinediones for patients with type II diabetes in Taiwan. Wen YW, Tsai YW, Huang WF et al. Pharmacoepidemiol Drug Saf. 2011 Jan. PMID: 21182151 Should the Metabolic Syndrome Patient with Prediabetes Be Offered Pharmacotherapy? Sullivan SD, Ratner RE. Curr Diab Rep. 2011 Jan 5. PMID: 21207204 Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. Toprani A, Fonseca V. Diabetes Obes Metab. 2010 Dec 6. PMID: 21205120 Pharmacotherapy of polycystic ovary syndrome - an update. Saha L, Kaur S, Saha PK. Fundam Clin Pharmacol. 2011 Jan 7. PMID: 21210850 [Tough glucose reduction necessary in newly diagnosed diabetes]. Rydén M. Lakartidningen. 2010 Nov 10-16. PMID: 21179867 [Pharmacological treatment of diabetes in the elderly]. García-Lara JM, Avila-Funes JA, Aguilar-Navarro S. Rev Invest Clin. 2010 Jul-Aug. PMID: 21222315 Hepatic steatosis and hepatitis C: Still unhappy bedfellows? Hwang SJ, Lee SD. J Gastroenterol Hepatol. 2011 Jan. PMID: 21199519 GLP-1 for type 2 diabetes. Ahrén B. Exp Cell Res. 2011 Jan 12. PMID: 21237153 GLP-1 for type 2 diabetes. Ahrén B. Exp Cell Res. 2011 Jan 12. PMID: 21237153 A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analog, in patients with type 2 diabetes. Barrington P, Chien JY, Showalter HD et al. Diabetes Obes Metab. 2011 Jan 19. PMID: 21251178 Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents. Pollex EK, Hutson JR. Expert Opin Drug Metab Toxicol. 2011 Jan 20. PMID: 21247371 Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. Khera AV, Cuchel M, de la Llera-Moya M et al. N Engl J Med. 2011 Jan 13. PMID: 21226578 Progress in the Development of New Drugs in Alzheimer ' s Disease. Piau A, Nourhashemi F, Hein C et al. J Nutr Health Aging. 2011. PMID: 21267520 [Comorbidity in heart failure.] Widmer F. Ther Umsch. 2011 Feb. PMID: 21271541 Type 2 Diabetes: Uses of thiazolidinediones and insulin. T Bloomgarden Z Md. Diabetes Care. 2011 Feb. PMID: 21270175 Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone. Kock G, Bringmann A, Held SA et al. Blood. 2011 Feb 4. PMID: 21296999 Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone. Kock G, Bringmann A, Held SA et al. Blood. 2011 Feb 4. PMID: 21296999 Rosiglitazone and pioglitazone aggravate doxorubicin-induced cardiomyopathy in Wistar rats. Saraogi P, Pillai KK, Singh BK et al. Biomed Pharmacother. 2010 Dec 31. PMID: 21295435 Rosiglitazone and pioglitazone aggravate doxorubicin-induced cardiomyopathy in Wistar rats. Saraogi P, Pillai KK, Singh BK et al. Biomed Pharmacother. 2010 Dec 31. PMID: 21295435 Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis and Meta-Regression Analysis of Placebo-Controlled Randomized Clinical Trials. Hernandez AV, Usmani A, Rajamanickam A et al. Am J Cardiovasc Drugs. 2011 Feb 3. PMID: 21294599 Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis and Meta-Regression Analysis of Placebo-Controlled Randomized Clinical Trials. Hernandez AV, Usmani A, Rajamanickam A et al. Am J Cardiovasc Drugs. 2011 Feb 3. PMID: 21294599 Thermogenesis and related metabolic targets in anti-diabetic therapy. Arch JR. Handb Exp Pharmacol. 2011. PMID: 21484574 Thermogenesis and related metabolic targets in anti-diabetic therapy. Arch JR. Handb Exp Pharmacol. 2011. PMID: 21484574 Targeting type 2 diabetes. Schwanstecher C, Schwanstecher M. Handb Exp Pharmacol. 2011. PMID: 21484565 Targeting type 2 diabetes. Schwanstecher C, Schwanstecher M. Handb Exp Pharmacol. 2011. PMID: 21484565 Peroxisome proliferator-activated receptors: Targets for the treatment of metabolic illnesses (Review). Moore-Carrasco R, Poblete Bustamante M, González Guerra O et al. Mol Med Report. 2008 May-Jun. PMID: 21479412 Peroxisome proliferator-activated receptors: Targets for the treatment of metabolic illnesses (Review). Moore-Carrasco R, Poblete Bustamante M, González Guerra O et al. Mol Med Report. 2008 May-Jun. PMID: 21479412 Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients? García-Giménez JL, Sanchis-Gomar F, Pallardó FV. Mov Disord. 2011 Apr 5. PMID: 21469214 Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients? García-Giménez JL, Sanchis-Gomar F, Pallardó FV. Mov Disord. 2011 Apr 5. PMID: 21469214 Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM). Souto SB, Souto EB, Braga DC et al. Eur J Clin Pharmacol. 2011 Apr 6. PMID: 21468743 Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM). Souto SB, Souto EB, Braga DC et al. Eur J Clin Pharmacol. 2011 Apr 6. PMID: 21468743 Neurovascular function in Alzheimer's disease patients and experimental models. Nicolakakis N, Hamel E. J Cereb Blood Flow Metab. 2011 Apr 6. PMID: 21468088 Neurovascular function in Alzheimer's disease patients and experimental models. Nicolakakis N, Hamel E. J Cereb Blood Flow Metab. 2011 Apr 6. PMID: 21468088 Adiponectin and Cardiovascular Health: an Update. Hui X, Lam KS, Vanhoutte PM et al. Br J Pharmacol. 2011 Apr 1. PMID: 21457225 Adiponectin and Cardiovascular Health: an Update. Hui X, Lam KS, Vanhoutte PM et al. Br J Pharmacol. 2011 Apr 1. PMID: 21457225 Oral Pioglitazone Reduces Infarction Volume and Improves Neurologic Function Following MCAO in Rats. Blankenship D, Niemi J, Hilow E et al. Adv Exp Med Biol. 2011. PMID: 21445783 Oral Pioglitazone Reduces Infarction Volume and Improves Neurologic Function Following MCAO in Rats. Blankenship D, Niemi J, Hilow E et al. Adv Exp Med Biol. 2011. PMID: 21445783 Synthesis of spirocyclic thiazolidinediones using ring-closing metathesis and one-pot sequential ring-closing/cross metathesis. Dhara K, Paladhi S, Midya GC et al. Org Biomol Chem. 2011 Mar 28. PMID: 21445390 Synthesis of spirocyclic thiazolidinediones using ring-closing metathesis and one-pot sequential ring-closing/cross metathesis. Dhara K, Paladhi S, Midya GC et al. Org Biomol Chem. 2011 Mar 28. PMID: 21445390 [Cardial target-organ damage in diabetes.] Motz W, Kerner W. Internist (Berl). 2011 Apr 15. PMID: 21491115 Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning. Hall GC, Smith HT, Curtis B et al. Int J Clin Pract. 2011 May. PMID: 21489082 Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents. Higgins LG, Hayes JD. Drug Metab Rev. 2011 May. PMID: 21495793 Role for PPAR{gamma} in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. Morán-Salvador E, López-Parra M, García-Alonso V et al. FASEB J. 2011 Apr 19. PMID: 21507897 Role for PPAR{gamma} in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. Morán-Salvador E, López-Parra M, García-Alonso V et al. FASEB J. 2011 Apr 19. PMID: 21507897 Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Younk LM, Uhl L, Davis SN. Expert Opin Drug Metab Toxicol. 2011 Apr 27. PMID: 21521130 Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Tseng CH. Diabetologia. 2011 May 5. PMID: 21544514 Type 2 diabetes can be prevented with early pharmacological intervention. Defronzo RA, Abdul-Ghani M. Diabetes Care. 2011 May. PMID: 21525456 Sitagliptin Compared to Thiazolidinediones as a Third-Line Oral Anti-Hyperglycemic Agent in Type 2 Diabetes Mellitus. Hsia SH, Navar MD, Duran P et al. Endocr Pract. 2011 May 6. PMID: 21550951 Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment. Narang N, Armstead SI, Stream A et al. Diab Vasc Dis Res. 2011 Apr. PMID: 21562061 Effects of insulin and other antihyperglycemic agents on lipid profiles of patients with diabetes. Chaudhuri A, Dandona P. Diabetes Obes Metab. 2011 May 13. PMID: 21569185 Effects of insulin and other antihyperglycemic agents on lipid profiles of patients with diabetes. Chaudhuri A, Dandona P. Diabetes Obes Metab. 2011 May 13. PMID: 21569185 Norlichexanthone Isolated from Fungus P16 Promotes the Secretion and Expression of Adiponectin in Cultured ST-13 Adipocytes. Ikeda M, Kurotobi Y, Namikawa A et al. Med Chem. 2011 May 16. PMID: 21568875 Norlichexanthone Isolated from Fungus P16 Promotes the Secretion and Expression of Adiponectin in Cultured ST-13 Adipocytes. Ikeda M, Kurotobi Y, Namikawa A et al. Med Chem. 2011 May 16. PMID: 21568875 A Structured Self-Monitoring of Blood Glucose Approach in Type 2 Diabetes Encourages More Frequent, Intensive, and Effective Physician Interventions: Results from the STeP Study. Polonsky WH, Fisher L, Schikman CH et al. Diabetes Technol Ther. 2011 May 13. PMID: 21568751 A Structured Self-Monitoring of Blood Glucose Approach in Type 2 Diabetes Encourages More Frequent, Intensive, and Effective Physician Interventions: Results from the STeP Study. Polonsky WH, Fisher L, Schikman CH et al. Diabetes Technol Ther. 2011 May 13. PMID: 21568751 Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis. Gross JL, Kramer CK, Leitão CB et al. Ann Intern Med. 2011 May 17. PMID: 21576535 Clinical review: Adiponectin biology and its role in inflammation and critical illness. Robinson K, Prins J, Venkatesh B. Crit Care. 2011 Apr 20. PMID: 21586104 Clinical review: Adiponectin biology and its role in inflammation and critical illness. Robinson K, Prins J, Venkatesh B. Crit Care. 2011 Apr 20. PMID: 21586104 ANDROGENS AND ESTROGENS PREVENT ROSIGLITAZONE-INDUCED ADIPOGENESIS IN HUMAN MESENCHYMAL STEM CELLS. Benvenuti S, Cellai I, Luciani P et al. J Endocrinol Invest. 2011 May 19. PMID: 21597316 Diabetes mellitus: new drugs for a new epidemic. Nicholson G, Hall GM. Br J Anaesth. 2011 May 24. PMID: 21610015 Drug safety of rosiglitazone and pioglitazone in France : a study using the French PharmacoVigilance database. Berthet S, Olivier P, Montastruc JL et al. BMC Clin Pharmacol. 2011 May 24. PMID: 21609444 [Steatosis and steatohepatitis in diabetic patient]. Hůlek P, Dresslerová I. Vnitr Lek. 2011 Apr. PMID: 21612059 Challenge of Creating Single-agents for the Treatment of Type 1 and 2 Diabetes by Targeting Retinoid X Receptor. Kakuta H. Yakugaku Zasshi. 2011. PMID: 21628978 Comparison of Direct Action of Thiazolidinediones and Glucocorticoids on Renal Podocytes: Protection from Injury and Molecular Effects. Agrawal S, Guess AJ, Benndorf R et al. Mol Pharmacol. 2011 Jun 2. PMID: 21636793 Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. Aguilar RB. Clin Ther. 2011 Apr. PMID: 21635988 Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Ovalle F. Clin Ther. 2011 Apr. PMID: 21635987 Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Filion KB, Joseph L, Boivin JF et al. Pharmacoepidemiol Drug Saf. 2011 Jun 13. PMID: 21671441 [Thiazolidinediones]. Nakamura T, Ueda Y. Nippon Rinsho. 2010 Nov. PMID: 21661186 Glycemic index differences of high-fat diets modulate primarily lipid metabolism in murine adipose tissue. Van Schothorst EM, Bunschoten A, Verlinde E et al. Physiol Genomics. 2011 Jun 14. PMID: 21673076 Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Betteridge DJ. Diabet Med. 2011 Jul. PMID: 21672000 Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit. Papaetis GS, Orphanidou D, Panagiotou TN. Curr Drug Targets. 2011 Jun 15. PMID: 21675944 Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus. Kruger DF, Boucher JL, Banerji MA. Postgrad Med. 2011 Jul. PMID: 21680989 Pleiotropic effects of glitazones: a double edge sword? Salomone S. Front Pharmacol. 2011. PMID: 21687509 Intensive glucose lowering and cardiovascular outcomes. Winterstein AG, Heckbert SR, Schambelan M. N Engl J Med. 2011 Jun 9. PMID: 21651404 Preservation of {beta}-Cell Function: The Key to Diabetes Prevention. Defronzo RA, Abdul-Ghani MA. J Clin Endocrinol Metab. 2011 Jun 22. PMID: 21697254 [Diabetes and osteoporosis.] Valkusz Z. Orv Hetil. 2011 Jul 1. PMID: 21712181 Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones? Ratziu V, Pienar L. Hepatol Res. 2011 Jul. PMID: 21711428 Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver. Oishi K, Tomita T. Biol Pharm Bull. 2011. PMID: 21720023 Thiazolidinediones regulate adipose lineage dynamics. Tang W, Zeve D, Seo J et al. Cell Metab. 2011 Jul 6. PMID: 21723509 Anti-Inflammatory and Antioxidant Properties of a New Arylidene-Thiazolidinedione in Macrophages. Faine LA, Rudnicki M, César FA et al. Curr Med Chem. 2011 Jul 4. PMID: 21728966 Bennett WL, Wilson LM, Bolen S et al. . 2011 Mar. PMID: 21735563 Osteoporosis and risk of fracture in patients with diabetes: an update. Montagnani A, Gonnelli S, Alessandri M et al. Aging Clin Exp Res. 2011 Apr. PMID: 21743287 Synthesis and antidiabetic activity of morpholinothiazolyl-2,4-thiazolidindione derivatives. Ezer M, Yıldırım LT, Bayro O et al. J Enzyme Inhib Med Chem. 2011 Jul 8. PMID: 21740103 Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis (NASH): A 12 month-randomized, prospective, open- label trial. Torres D, Jones F, Shaw J et al. Hepatology. 2011 Jul 11. PMID: 21748770 The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Van Wagner LB, Rinella ME. Therap Adv Gastroenterol. 2011 Jul. PMID: 21765869 [The role of PPARs and his isoforms in the metabolic disorder related to insulin resistance and diabetes]. . Tsitol Genet. 2011 May-Jun. PMID: 21774406 PPAR{gamma}-Independent Increase in Glucose Uptake and Adiponectin Abundance in Fat Cells. Dubuisson O, Dhurandhar EJ, Krishnapuram R et al. Endocrinology. 2011 Jul 26. PMID: 21791563 Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery. Rusinova R, Herold KF, Sanford RL et al. J Gen Physiol. 2011 Aug. PMID: 21788612 The impact of diabetes on the pathogenesis of sepsis. Koh GC, Peacock SJ, van der Poll T et al. Eur J Clin Microbiol Infect Dis. 2011 Jul 30. PMID: 21805196 High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors. Miduturu CV, Deng X, Kwiatkowski N et al. Chem Biol. 2011 Jul 29. PMID: 21802008 Adipocytokines: The pied pipers. Gandhi H, Upaganlawar A, Balaraman R. J Pharmacol Pharmacother. 2010 Jan. PMID: 21808585 Discordant Effects on Central Obesity, Hepatic Insulin Resistance, and Alanine Aminotransferase of Low-dose Metformin and Thiazolidinedione Combination Therapy in Patients with Impaired Glucose Tolerance. Retnakaran R, Ye C, Hanley AJ et al. Diabetes Obes Metab. 2011 Aug 3. PMID: 21812893 Epinephrine Induces PDK4 mRNA Expression in Adipose Tissue From Obese, Insulin Resistant Rats. Wan Z, Frier BC, Williams DB et al. Obesity (Silver Spring). 2011 Aug 4. PMID: 21818153 A Method for the Simultaneous Determination of 3T3-L1 Adipocyte Metabolites by Liquid Chromatography/Mass Spectrometry Using [(13)C]-stable Isotopes. Nagai H, Goto T, Takahashi N et al. Biosci Biotechnol Biochem. 2011 Aug 7. PMID: 21821950 The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Phielix E, Szendroedi J, Roden M. Trends Pharmacol Sci. 2011 Aug 6. PMID: 21824668 [Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents]. Mori Y. Nihon Rinsho. 2011 Aug. PMID: 21838054 [Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents]. Mori Y. Nihon Rinsho. 2011 Aug. PMID: 21838054 Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics. 2011 Aug. PMID: 21843065 Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics. 2011 Aug. PMID: 21843065 Noninsulin pharmacological management of type 1 diabetes mellitus. Garg V. Indian J Endocrinol Metab. 2011 Jul. PMID: 21847455 Mechanism for anti-oxidative effects of thiazolidinediones in pancreatic {beta}-cells. Chung SS, Kim M, Lee JS et al. Am J Physiol Endocrinol Metab. 2011 Aug 16. PMID: 21846907 Pharmacological Management of Type 2 Diabetes Mellitus: An Update. El-Kaissi S, Sherbeeni S. Curr Diabetes Rev. 2011 Aug 17. PMID: 21846326 Glucolipotoxicity and beta cells in type 2 diabetes mellitus: Target for durable therapy? van Raalte DH, Diamant M. Diabetes Res Clin Pract. 2011 Aug. PMID: 21864750 The use of optical coherence tomography to determine the effect of thiazolidinediones on retinal thickness in patients with type 2 diabetes. Tarbett AK, Vanroekel LR, Howard RS et al. J Diabetes Sci Technol. 2011 Jul 1. PMID: 21880238 Association of Type 2 Diabetes and Colon Adenomas. Eddi R, Karki A, Shah A et al. J Gastrointest Cancer. 2011 Sep 6. PMID: 21894459 Effect of thiazolidinediones on the erythropoeitic and germinal cells in the male wistar rats. Rabbani SI, Devi K, Khanam S. Clin Med Oncol. 2008. PMID: 21892311 The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Ye Y, Perez-Polo JR, Aguilar D et al. Basic Res Cardiol. 2011 Sep 4. PMID: 21892746 AMP-activated protein kinase pathway and bone metabolism. Jeyabalan J, Shah M, Chenu C. J Endocrinol. 2011 Sep 8. PMID: 21903861 [Nuclear receptors PPAR as a drug target in metabolic disorders]. Stolarczyk M, Gutman W, Derlacz RA. Postepy Biochem. 2011. PMID: 21913422 Insulin Sensitizers May Attenuate Lean Mass Loss in Older Men With Diabetes. Lee CG, Boyko EJ, Barrett-Connor E et al. Diabetes Care. 2011 Sep 16. PMID: 21926282 Drug-induced heart failure. Maxwell CB, Jenkins AT. Am J Health Syst Pharm. 2011 Oct 1. PMID: 21930637 Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Chao TF, Leu HB, Huang CC et al. Int J Cardiol. 2011 Sep 17. PMID: 21930315 Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics. Sun H, Scott DO. Chem Biol Interact. 2011 Sep 10. PMID: 21939641 Pioglitazone is a Valid Alternative to Rosiglitazone. Derosa G. Am J Cardiovasc Drugs. 2011 Sep 27. PMID: 21950735 Proportion of patients at HbA1c target <7% with 8 classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Esposito K, Chiodini P, Bellastella G et al. Diabetes Obes Metab. 2011 Sep 29. PMID: 21958121 Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: The SIROCO study. Lazich I, Sarafidis P, de Guzman E et al. Diabetes Obes Metab. 2011 Sep 28. PMID: 21955403 Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators. Adeghate E, Adem A, Hasan MY et al. Open Med Chem J. 2011. PMID: 21966330 Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. Klarenbach S, Cameron C, Singh S et al. CMAJ. 2011 Oct 3. PMID: 21969406 Regulation of lipoprotein lipase gene expression by insulin and troglitazone in rainbow trout (Oncorhynchus mykiss) adipocyte cells in culture. Bouraoui L, Cruz-Garcia L, Gutiérrez J et al. Comp Biochem Physiol A Mol Integr Physiol. 2011 Sep 22. PMID: 21967882 Rosiglitazone reverses increased duodenal inhibitory response in spontaneously hypertensive rats. De Benedictis L, Potenza MA, Gagliardi S et al. Neurogastroenterol Motil. 2011 Oct 14. PMID: 21995307 Cellular and molecular effects of thiazolidinediones on bone cells: a review. Mabilleau G, Chappard D, Baslé MF. Int J Biochem Mol Biol. 2011. PMID: 22003436 Differentiation potential of pancreatic fibroblastoid cells/stellate cells: effects of peroxisome proliferator-activated receptor gamma ligands. Kruse ML, Hopf-Jensen S, Timke C et al. Int J Cell Biol. 2011. PMID: 22007221 Prediabetes: To treat or not to treat? Moutzouri E, Tsimihodimos V, Rizos E et al. Eur J Pharmacol. 2011 Oct 12. PMID: 22020287 Risk Factors for Hypoglycemia-Related Hospitalization in Patients with Type 2 Diabetes: A Nested Case-Control Study. Quilliam BJ, Simeone JC, Ozbay AB. Clin Ther. 2011 Oct 20. PMID: 22018449 Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. Dave DJ. J Pharmacol Pharmacother. 2011 Oct. PMID: 22025849 Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials. Monami M, Dicembrini I, Antenore A et al. Diabetes Care. 2011 Nov. PMID: 22025784 Targeting sp1 Transcription Factors in Prostate Cancer Therapy. Sankpal UT, Goodison S, Abdelrahim M et al. Med Chem. 2011 Sep 1. PMID: 22022994 Pharmacotherapy for the Metabolic Syndrome. Swislocki AL, Siegel D, Jialal I. Curr Vasc Pharmacol. 2011 Oct 21. PMID: 22022773 Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. The TIDE Trial Investigators. Diabetologia. 2011 Oct 29. PMID: 22038523 Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. McIntosh B, Cameron C, Singh SR et al. Open Med. 2011. PMID: 22046219 Selective Peroxisome Proliferator-Activated Receptor- Modulation to Reduce Cardiovascular Risk in Patients with Insulin Resistance. Yew T, Toh SA, Millar JS. Recent Pat Cardiovasc Drug Discov. 2011 Oct 21. PMID: 22044303 Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Boettcher E, Csako G, Pucino F et al. Aliment Pharmacol Ther. 2011 Nov 4. PMID: 22050199 The anti-proliferative effect of rosiglitazone on angiotensin II-induced vascular smooth muscle cell proliferation is mediated by the mTOR pathway. Kim JS, Kim IK, Lee SY et al. Cell Biol Int. 2011 Nov 4. PMID: 22050182 Transitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia. Peterson G. Hosp Pract (Minneap). 2011 Nov. PMID: 22056828 Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Chaudhuri A, Rosenstock J, Digenio A et al. Diabetes Metab Res Rev. 2011 Nov 12. PMID: 22081557 Privileged Scaffolds or Promiscuous Binders - A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry. Mendgen T, Steuer C, Klein CD. J Med Chem. 2011 Nov 14. PMID: 22077389 The effects of exenatide BID on metabolic control, medication use, and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review. Best JH, Lavillotti K, Deyoung MB et al. Diabetes Obes Metab. 2011 Nov 10. PMID: 22074017 Metabolic syndrome and hepatic resection: improving outcome. Agrawal S, Daruwala C. HPB (Oxford). 2011 Dec. PMID: 22081919 Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. Castagno D, Baird-Gunning J, Jhund PS et al. Am Heart J. 2011 Nov. PMID: 22093212 Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. He X, Esteva FJ, Ensor J et al. Ann Oncol. 2011 Nov 22. PMID: 22112968 Incidence of Cardiovascular Events in Which 2 Thiazolidinediones Are Used as Add-on Treatments for Type 2 Diabetes Mellitus in a Taiwanese Population. Chou CC, Chen WL, Kao TW et al. Clin Ther. 2011 Nov 23. PMID: 22118894 Synthesis and antihyperglycemic evaluation of new 2,4-thiazolidinediones having biodynamic aryl sulfonylurea moieties. Jawale DV, Pratap UR, Rahuja N et al. Bioorg Med Chem Lett. 2011 Nov 9. PMID: 22123321 Synthesis and antihyperglycemic evaluation of new 2,4-thiazolidinediones having biodynamic aryl sulfonylurea moieties. Jawale DV, Pratap UR, Rahuja N et al. Bioorg Med Chem Lett. 2011 Nov 9. PMID: 22123321 Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. van Staa TP, Patel D, Gallagher AM et al. Diabetologia. 2011 Nov 30. PMID: 22127412 Antidiabetes Drugs Correlate With Decreased Risk of Lung Cancer: A Population-Based Observation in Taiwan. Lai SW, Liao KF, Chen PC et al. Clin Lung Cancer. 2011 Nov 28. PMID: 22129971 Diabetes and fracture healing: the skeletal effects of diabetic drugs. Simpson CM, Calori GM, Giannoudis PV. Expert Opin Drug Saf. 2011 Dec 6. PMID: 22145960 Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data. Gallagher AM, Smeeth L, Seabroke S et al. PLoS One. 2011. PMID: 22164237 Substituent and solvent effects on intramolecular charge transfer of 5-arylidene-2,4-thiazolidinediones. Rančić M, Trišović N, Milčić M et al. Spectrochim Acta A Mol Biomol Spectrosc. 2011 Nov 17. PMID: 22153743 Peroxisome proliferator-activated receptor gamma agonists repress epithelial sodium channel expression in the kidney. Borsting E, Cheng VP, Glass CK et al. Am J Physiol Renal Physiol. 2011 Dec 14. PMID: 22169011 The Antidiabetic Drug Ciglitazone Induces High Grade Bladder Cancer Cells Apoptosis through the Up-Regulation of TRAIL. Plissonnier ML, Fauconnet S, Bittard H et al. PLoS One. 2011. PMID: 22174792 Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with NAFLD. Lomonaco R, Ortiz-Lopez C, Orsak B et al. Hepatology. 2011 Dec 20. PMID: 22183689 Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with NAFLD. Lomonaco R, Ortiz-Lopez C, Orsak B et al. Hepatology. 2011 Dec 20. PMID: 22183689 Medical management of metabolic dysfunction in PCOS. Duleba AJ. Steroids. 2011 Dec 13. PMID: 22182833 Medical management of metabolic dysfunction in PCOS. Duleba AJ. Steroids. 2011 Dec 13. PMID: 22182833 Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus. Namvaran F, Rahimi-Moghaddam P, Azarpira N et al. Mol Biol Rep. 2011 Dec 21. PMID: 22187345 Peroxisome proliferating activating receptor gamma-independent attenuation of interleukin 6 and interleukin 8 secretion from primary endometrial stromal cells by thiazolidinediones. McKinnon B, Bersinger NA, Mueller MD. Fertil Steril. 2011 Dec 20. PMID: 22192353 The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Cai L, Cai Y, Lu ZJ et al. J Clin Pharm Ther. 2011 Dec 22. PMID: 22191695 Within-person study designs had lower precision and greater susceptibility to bias because of trends in exposure than cohort and nested case-control designs. Nicholas JM, Grieve AP, Gulliford MC. J Clin Epidemiol. 2011 Dec 23. PMID: 22197519 Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Bennett WL, Odelola OA, Wilson LM et al. Ann Intern Med. 2012 Jan 3. PMID: 22213492 Waugh N, Cummins E, Royle P et al. . 2009 May. PMID: 22220324 Rosiglitazone and pioglitazone alter aromatase kinetic properties in human granulosa cells. Araki T, Varadinova M, Goldman M et al. PPAR Res. 2011. PMID: 22220166 Editorial: hepatocellular carcinoma in type 2 diabetes: more than meets the eye. Baffy G. Am J Gastroenterol. 2012 Jan. PMID: 22218030 Thiazolidinedione dependent activation of sphingosine kinase 1 causes an anti-fibrotic effect in renal mesangial cells. Koch A, Völzke A, Wünsche C et al. Br J Pharmacol. 2012 Jan 5. PMID: 22221312 Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization. Saraf N, Sharma PK, Mondal SC et al. J Pharm Pharmacol. 2012 Feb. PMID: 22221092 Weight changes and their predictors amongst 11,140 patients with type 2 diabetes in the ADVANCE trial. van Dieren S, Czernichow S, Chalmers J et al. Diabetes Obes Metab. 2012 Jan 9. PMID: 22226008 Pioglitazone inhibits platelet function and potentiates the effects of aspirin: A prospective observation study. Mongan J, Mieszczanska HZ, Smith BH et al. Thromb Res. 2012 Jan 4. PMID: 22225857 Molecular mechanisms of diabetes and atherosclerosis: Role of adiponectin. Kishida K, Funahashi T, Shimomura I. Endocr Metab Immune Disord Drug Targets. 2012 Jan 11. PMID: 22236026 Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches. Siasos G, Tousoulis D, Kollia C et al. Curr Med Chem. 2012 Jan 17. PMID: 22257055 Type 2 diabetes and bone fractures. Moseley KF. Curr Opin Endocrinol Diabetes Obes. 2012 Jan 18. PMID: 22262002 Distinct Effects of Pioglitazone and Metformin on Circulating Sclerostin and Biochemical Markers of Bone Turnover in Men with Type 2 Diabetes Mellitus. van Lierop AH, Hamdy N, van der Meer RW et al. Eur J Endocrinol. 2012 Jan 20. PMID: 22267280 Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Musso G, Cassader M, Rosina F et al. Diabetologia. 2012 Jan 27. PMID: 22278337 Raising HDL-C can be achieved by both lifestyle changes and pharmacological means. Introduction. Barter P. Atheroscler Suppl. 2011 Nov. PMID: 22272435